Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- ESMO 2017: Recommendations From Dr. Lee Schwartzberg
- Improved Efficacy of Palbociclib vs Chemotherapy for the Treatment of Postmenopausal Women With HR+/HER2− Advanced/Metastatic Breast Cancer
- Ipatasertib Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer
- Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer
- Cytotoxic Tumor-Infiltrating Lymphocytes for Predicting Outcomes in Metastatic HER2-Positive Breast Cancer
- Non-BRCA Genetic Predisposition to Breast Cancer Among Ashkenazi Jewish Women
- Decreased Gastrointestinal Toxicity Associated With a Novel Capecitabine Schedule (7 Days On and 7 Days Off)
- Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer
- Germline Mutation Status and Outcomes in Triple-Negative Breast Cancer
- Consensus Conference on De-Escalating and Escalating Treatments for Early-Stage Breast Cancer